Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation (NASDAQ:AMRN) announced Q3 2022 financial results, reporting a net revenue of $89.9 million, down 37% from Q3 2021, largely due to increasing generic competition affecting VASCEPA sales. The company secured positive reimbursement assessments in several European markets, including Finland and the Netherlands, and launched VAZKEPA in the UK. Efforts to stabilize US revenues continued, achieving a cash-positive quarter excluding restructuring charges. Amarin's cost-saving measures are projected to yield $100 million by mid-2023, extending its cash runway amid ongoing market access negotiations.
Amarin Corporation plc (NASDAQ:AMRN) has announced the retirement of Lars Ekman and Patrick O’Sullivan from its Board of Directors effective year-end, following a significant refreshment program. Adam Berger and Geraldine Murphy are appointed as new independent directors, contributing extensive international experience in healthcare and finance. With 75% of the board refreshed over the past year, the company aims to enhance its expertise to support global expansion and strategic objectives. This leadership change is designed to align with Amarin's mission to advance cardiovascular disease management.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on October 27, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results. The call follows the pre-market release of the financial results. Interested parties can access the live call through the investor relations section of Amarin's website or via dial-in options provided for both U.S. and international participants. A replay of the call will also be available after the event through the website.
Amarin Corporation plc (NASDAQ:AMRN) announced significant changes in its Board of Directors, emphasizing an active board refreshment process. The board supports a new strategic direction aimed at expanding its business in Europe and enhancing U.S. operations. In 2022, three independent directors with extensive biotech and pharmaceutical experience were appointed. The board is in the final stages of appointing new directors and remains committed to constructive engagement with shareholders, including Sarissa Capital Management.
Sarissa Capital Management has expressed concerns over Amarin Corporation's management, urging immediate representation on the board to restore shareholder value. Sarissa highlighted that shareholders have lost over $850 million this year, with a 64% stock decline. Following the annual meeting, stock prices dropped another 38%, equating to a loss of $280 million for shareholders. Sarissa warns that continued mismanagement may lead to cash shortages and the need for dilutive capital raises. They plan to solicit votes for new board members at a special meeting.
Amarin Corporation plc (NASDAQ:AMRN) announced that Karim Mikhail, the president and CEO, will speak at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 9:00 a.m. ET. This event will take place in New York City from September 12-14, 2022. A live webcast of the presentation will be available here.
Amarin focuses on cardiovascular disease management and aims to advance treatments through scientific understanding.
Amarin Corporation (NASDAQ:AMRN) announced significant findings from its REDUCE-IT study, presented at the ESC Congress 2022. The data reveals that VASCEPA/VAZKEPA (icosapent ethyl) reduced first cardiovascular events by 23% in current smokers and 29% in former smokers compared to placebo. The incidence of cardiovascular events in current and former smokers using IPE was similar to that of never smokers. These results highlight the potential of IPE in mitigating cardiovascular risks associated with smoking history.
Amarin Corporation announced significant findings from the REDUCE-IT study presented at the ESC Congress 2022 in Barcelona. The study revealed that VASCEPA/VAZKEPA (icosapent ethyl) led to a 40% reduction in ST-segment elevation myocardial infarction (STEMI) and a 27% reduction in non-ST segment elevated myocardial infarction (NSTEMI) in patients with cardiovascular disease or diabetes. The study involved 8,179 patients and showed that IPE reduced the primary composite endpoint by 25% and the secondary endpoint by 26%. These results highlight the potential of IPE in managing cardiovascular risks.
Amarin Corporation plc (NASDAQ:AMRN) announced new research on VASCEPA/VAZKEPA's effects in cardiovascular patients accepted for presentation at the ESC Congress in Barcelona from August 26-29, 2022. Key findings include a Late-Breaking Science presentation on ST-segment Elevation MI reduction based on the REDUCE-IT trial. The data emphasizes VASCEPA's role in reducing cardiovascular risk, especially among high-risk groups, reinforcing findings from the REDUCE-IT study.
Amarin Corporation (NASDAQ:AMRN) announced a positive reimbursement decision for VAZKEPA from the UK’s NICE and initiated market access negotiations across Europe. The company aims for $100 million in cost savings over the next year in response to increasing competition. Q2 2022 net revenue was $94.4 million, down 39% from the previous year, primarily due to generic competition in the U.S. Amarin reported a net loss of $70 million. Despite challenges, the company is focused on expanding internationally and improving its financial position.